Navigation Links
2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion

REGENSBURG, Germany, May 10th, 2007 - Antisense Pharma, a German biopharmaceutical company specialized in targeted therapies for malignant tumors, today announced, that data from the Phase IIb-study with AP 12009 in high-grade glioma will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held in Chicago, Illinois, U.S.A, from June 1st - 5th.

In the open-label, randomized dose-finding Phase IIb-trial adult patients with recurrent or refractory high-grade glioma were treated either with one of two doses of the TGF-beta2 inhibitor AP 12009 - applied by convection-enhanced delivery - or chemotherapy (temozolomide or PCV) as a control. Survival data in the subgroup of anaplastic astrocytoma patients suggest superiority of AP 12009 over chemotherapeutic treatment.

Median overall survival has not yet been reached in both AP 12009 dose groups in contrast to 91 weeks in the chemotherapy treatment group. Overall response rates demonstrate a benefit of AP 12009 over chemotherapy. The duration of long-term tumor responses until now exceeds the active treatment period by far.

“The significance of our clinical research findings is reflected by the fact, that the Scientific Program Committee has chosen the data for poster discussion among many high quality abstracts”, says the coordinating investigator of the study, Prof. Ulrich Bogdahn, MD, University of Regensburg, Germany. Data from the Phase IIb-study on efficacy and safety in anaplastic astrocytoma patients will be discussed by Albert J. Wong, MD on Sunday June 3rd 2007 in the session “Central Nervous System Tumors” from 11:15 a.m. to 11:30 a.m. in room S100a on Level 1 of McCormick Place South Building.

Prof. Bogdahn will be available for further discussion at the poster entitled “A Phase IIb actively controlled study with the TGF-beta2 inhibito
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
5. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
6. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
7. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
8. MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia
9. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
Post Your Comments:
(Date:9/4/2015)... , September 4, 2015 ... announces that Hutchison MediPharma Limited ("HMP"), its drug ... the second proof-of-concept ("POC") trial of fruquintinib in ... ("NSCLC") in China .  The ... in meeting the primary efficacy endpoint of progression ...
(Date:9/3/2015)... India , Sept. 3, 2015  Cipla, a ... meet the everyday needs of all patients, today announced ... definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals ... to certain closing conditions, is valued at $550 million ... revenue from these transactions is over $200 million for ...
(Date:9/3/2015)... -- Report Details Ovarian Cancer Therapies ... and Emerging Opportunities What,s the future for treating ... forecasts those pharmaceutical revenues. There you find outlooks ... explore trends, results, treatments, R&D, and opportunities, seeing ... to 2025 at overall world market, submarket, product ...
Breaking Medicine Technology:Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6
... - Antigenics Inc.,(NASDAQ: AGEN) today announced additional ... therapeutic cancer vaccine,Oncophage(R) (vitespen). The end-of-study results, ... showed that in a substantial,subset of patients ... disease,recurrence, Oncophage demonstrated a clinically significant,improvement in ...
... product recently approved by FDA for long-term,maintenance ... formoterol fumarate provides improved lung function,comparable to ... and positive safety profile -- , NAPA, ... at the,International Conference of the American Thoracic ...
Cached Medicine Technology:Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 2Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 3Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 5Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® ... medical devices, announced its only mission and research focus: Water Life Science®. In ... Kleyne, body water evaporation is becoming dangerously accelerated. As a result of the ...
(Date:9/4/2015)... ... September 04, 2015 , ... The USC Eye Institute is proud to announce ... Doximity. Faculty, residents and staff are honored to have contributed to the success ... our ophthalmology residency program. Our faculty places a high priority on our educational programs ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference program ... Hollywood, Florida October 9-10, 2015 at the Diplomat Resort & Spa has been ... doctors and researchers at the top of their field and will be presenting ...
(Date:9/4/2015)... ... 04, 2015 , ... Having access to a doctor can sometimes be a ... of unnecessary emergency room visits which affects hospitals’ abilities to provide quality service to ... a solution to alleviate this problem has recently presented itself, the new telemedicine platform ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... its first neighborhood created specifically for adults with intellectual, developmental and acquired disabilities. ... area and feature 30 cottage or “pocket” homes. In this community, adults will ...
Breaking Medicine News(10 mins):Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4
... of Vulnerability Management and Operational Whitelisting and Discuss Today,s ... ... Scottsdale, Ariz. (PRWEB) August ... __title__ Vulnerability Management Solutions], a recognized, global leader in ...
... allergies aren,t avoiding the foods they know they shouldn,t eat. ... epinephrine as often as they should be. And instructors, roommates ... if a food-allergic student has a reaction. , These are ... of Michigan Health System. The research suggests that many college ...
... Scott Kornhauser,announced the appointment of Marquita Collins as ... than 20 years of,healthcare industry experience., Her ... of,Aptiv Technology Partners and Regional Operations Director for ... and managing the,entire professional services team and full ...
... NCST ; TSX: NCS), a developer and manufacturer of ... financial results for the second quarter 2008 on Tuesday, August ... 9:00 AM ET on Wednesday,August 13, 2008 to discuss the ... Date: Wednesday, ...
... nevirapine could have downside, study finds , , TUESDAY, Aug. ... used in developing countries to prevent transmission of ... breast milk and blood of mothers, a new Stanford ... the risk that they and their children will develop ...
... emphasize measurement gaps and harmonization, WASHINGTON, ... assessing,clinician performance that can promote higher quality ... endorsed 67 clinician-level consensus,standards relating to cancer ... by thousands of medical professionals who are ...
Cached Medicine News:Health News:Lumension Security To Showcase Vulnerability Management Expertise With Whitehatworld.com Webcast 2Health News:Lumension Security To Showcase Vulnerability Management Expertise With Whitehatworld.com Webcast 3Health News:Students with food allergies often not prepared 2Health News:Students with food allergies often not prepared 3Health News:NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008 2Health News:HIV Drug Might Spur Resistant Strains of Virus 2Health News:National Quality Forum Endorses National Consensus Standards Promoting Accountability and Public Reporting 2Health News:National Quality Forum Endorses National Consensus Standards Promoting Accountability and Public Reporting 3Health News:National Quality Forum Endorses National Consensus Standards Promoting Accountability and Public Reporting 4Health News:National Quality Forum Endorses National Consensus Standards Promoting Accountability and Public Reporting 5Health News:National Quality Forum Endorses National Consensus Standards Promoting Accountability and Public Reporting 6Health News:National Quality Forum Endorses National Consensus Standards Promoting Accountability and Public Reporting 7Health News:National Quality Forum Endorses National Consensus Standards Promoting Accountability and Public Reporting 8Health News:National Quality Forum Endorses National Consensus Standards Promoting Accountability and Public Reporting 9Health News:National Quality Forum Endorses National Consensus Standards Promoting Accountability and Public Reporting 10Health News:National Quality Forum Endorses National Consensus Standards Promoting Accountability and Public Reporting 11
...
The Tew cranial/spinal retractor is designed for posterior fossa or intraspinal microsurgery where retraction is required. Clinical applications are: Posterior fossa microsurgery and intraspinal micr...
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Medicine Products: